Tag: Manufacturing

Outlook for the contract manufacturing industry following the growing biologics pipeline

The recent years have portrayed the renaissance in the domain of biologics, as pharmaceutical industry has once again gained attention towards the production of bioproducts. In fact, in 2019, a total of 28 biopharmaceutical products (including monoclonal antibodies, recombinant proteins and gene therapies) were approved in the US. Further, over 8,000 biological pharmaceutical products are

Antibody Drug Conjugates (ADCs): A Deeper Look into Contract Manufacturing Landscape

Antibody Drug Conjugates (ADCs) known as the 21st Century Magic Bullets, have emerged as a promising class of targeted therapies being developed for the treatment of cancer. Two decades ago, in the year 2000, the domain witnessed the approval of first ADC known as Mylotarg®, by the US FDA.  This was followed by the successful

Peptide APIs – A Deeper Look Into Contract Manufacturing Market

The recent years have portrayed the renaissance of peptide APIs, as pharma industry has once again turned its attention towards the potential of therapeutic peptides. Adoption of peptides as therapeutic agents have side-lined some of the earlier concerns associated with them, such as bioavailability, and has led to manufacturing of high-quality peptides in a larger

Outsourcing has become a popular trend in ophthalmic drug development domai

Owing to various reasons, such as growing manufacturing demand, need for specialized facilities, equipment and operational expertise, and high costs of development associated with certain drugs / therapies, a number of innovator companies have demonstrated a preference to outsource certain aspects of ophthalmic drug development and production operations to contract service providers. Over 240 companies

Microbiome-based Live Biotherapeutics Contract Manufacturing: Rising Opportunities for Specialized CMOs / CDMOs

What is the current development pipeline of microbiome-based live biotherapeutics? With over 85 products under preclinical and clinical development, the current development pipeline of microbiome-based live biotherapeutics has several promising candidates, which are anticipated to get commercialized over the next few years. Hence, the demand for R&D and manufacturing services for such products is anticipated

Growing Pipeline of Microbiome-based Live Biotherapeutics Fuels the Manufacturing Demand

Live biotherapeutics are fragile bacteria, which require ideal conditions of heat, moisture and pH of products, to survive and prevent premature germination. In fact, manufacturing is presently one of the biggest bottlenecks in this domain; manufacturing such products is both technically challenging and financially demanding. One of the biggest challenges in the development of a

The Future of Manufacturing: Collaborative Robots in the Factories

The world has experienced a radical change with the advancements in technologies and systems that aid daily activities. Particularly, automation has played an important role in increasing the productivity and quality of the production process in various industries. Within the automation industry, robots have already been established; however, one of the fastest-growing segment of robotics

Cell Therapy Manufacturing: The USD 8 Billion+ Growth Opportunity

Cell Therapy have gained significant attention in the overall biopharmaceutical industry. The personalized nature of these treatment options render them highly specific and, according to a number of clinical studies, safe and efficacious. Around 20 such therapies have been approved so far; recent approvals include Alofisel® (2018), YESCARTA® (2017) and Kymriah® (2017). It is also

Pharmaceutical Contract Manufacturing: Current Market Landscape and Future Opportunities

 The present pipeline of pharmaceutical products is becoming increasingly complex and requires specialized facilities, equipment and operational expertise. In addition, the costs associated with acquiring manufacturing capabilities are exorbitant and, therefore, it is difficult for companies with limited finances and capacity constraints to succeed by themselves. Over the years, the contract manufacturing market has grown